JP7651481B2 - Ｃｄ３抗原結合断片およびそれを含む組成物 - Google Patents

Ｃｄ３抗原結合断片およびそれを含む組成物 Download PDF

Info

Publication number
JP7651481B2
JP7651481B2 JP2021576275A JP2021576275A JP7651481B2 JP 7651481 B2 JP7651481 B2 JP 7651481B2 JP 2021576275 A JP2021576275 A JP 2021576275A JP 2021576275 A JP2021576275 A JP 2021576275A JP 7651481 B2 JP7651481 B2 JP 7651481B2
Authority
JP
Japan
Prior art keywords
antigen
amino acid
seq
acid sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021576275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537824A (ja
JPWO2020264200A5 (enExample
Inventor
ヴォルカー シュレンベルガー
フィリップ クーン
アンドレ フレンツェル
ダラ マッキャン
ジェイムズ マクローリー
Original Assignee
アムニクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムニクス ファーマシューティカルズ， インコーポレイテッド filed Critical アムニクス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2022537824A publication Critical patent/JP2022537824A/ja
Publication of JPWO2020264200A5 publication Critical patent/JPWO2020264200A5/ja
Priority to JP2025040192A priority Critical patent/JP2025106277A/ja
Application granted granted Critical
Publication of JP7651481B2 publication Critical patent/JP7651481B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021576275A 2019-06-26 2020-06-25 Ｃｄ３抗原結合断片およびそれを含む組成物 Active JP7651481B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025040192A JP2025106277A (ja) 2019-06-26 2025-03-13 Ｃｄ３抗原結合断片およびそれを含む組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866746P 2019-06-26 2019-06-26
US62/866,746 2019-06-26
US202063041059P 2020-06-18 2020-06-18
US63/041,059 2020-06-18
PCT/US2020/039673 WO2020264200A1 (en) 2019-06-26 2020-06-25 Cd3 antigen binding fragments and compositions comprising same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025040192A Division JP2025106277A (ja) 2019-06-26 2025-03-13 Ｃｄ３抗原結合断片およびそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2022537824A JP2022537824A (ja) 2022-08-30
JPWO2020264200A5 JPWO2020264200A5 (enExample) 2023-06-30
JP7651481B2 true JP7651481B2 (ja) 2025-03-26

Family

ID=74059962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021576275A Active JP7651481B2 (ja) 2019-06-26 2020-06-25 Ｃｄ３抗原結合断片およびそれを含む組成物
JP2025040192A Pending JP2025106277A (ja) 2019-06-26 2025-03-13 Ｃｄ３抗原結合断片およびそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025040192A Pending JP2025106277A (ja) 2019-06-26 2025-03-13 Ｃｄ３抗原結合断片およびそれを含む組成物

Country Status (18)

Country Link
US (2) US20230121775A1 (enExample)
EP (1) EP3990497A4 (enExample)
JP (2) JP7651481B2 (enExample)
KR (1) KR20220038068A (enExample)
CN (1) CN115175933A (enExample)
AU (1) AU2020308868A1 (enExample)
BR (1) BR112021026089A2 (enExample)
CA (1) CA3143519A1 (enExample)
CL (1) CL2021003448A1 (enExample)
CO (1) CO2022000406A2 (enExample)
CR (1) CR20210628A (enExample)
DO (1) DOP2021000264A (enExample)
EC (1) ECSP22005986A (enExample)
IL (1) IL289102A (enExample)
MX (1) MX2021015880A (enExample)
PE (1) PE20220600A1 (enExample)
PH (1) PH12021500051A1 (enExample)
WO (1) WO2020264200A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019126576A1 (en) * 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND USES THEREOF
BR112023023650A2 (pt) 2020-04-04 2024-01-30 Janux Therapeutics Inc Composições e métodos relacionados a anticorpos ativados por tumores direcionados a egfr e antígenos de células efetoras
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021297984C1 (en) 2020-06-25 2025-12-11 Amunix Pharmaceuticals, Inc. HER-2 targeted bispecific compositions and methods for making and using the same
US11512113B2 (en) 2020-08-11 2022-11-29 Janux Therapeutics, Inc. Cleavable linker compositions and methods
LT4058474T (lt) * 2020-08-20 2024-08-26 A2 Biotherapeutics, Inc. Kompozicijos ir būdai, skirti gydyti egfr atžvilgiu teigiamas vėžio formas
WO2022125576A1 (en) 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
WO2022240865A1 (en) * 2021-05-11 2022-11-17 Janux Therapeutics, Inc. Antibodies targeting egfr and cd3 and uses thereof
CA3238167A1 (en) * 2021-11-19 2023-05-25 Maria Leia Smith Gpc3 binding agents, conjugates thereof and methods of using the same
US20250215110A1 (en) * 2022-04-01 2025-07-03 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
IL322564A (en) 2023-02-10 2025-10-01 Amunix Pharmaceuticals Inc Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use
KR20250166225A (ko) 2023-04-17 2025-11-27 아뮤닉스 파마슈티컬스, 인크. 표피 성장 인자 수용체를 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
CN120230203A (zh) * 2023-12-28 2025-07-01 四川思柏沃生物技术有限公司 抗cd3抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511521A (ja) 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP2014519322A (ja) 2011-05-16 2014-08-14 フェイビオン ファーマシューティカルズ， インコーポレイテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP2017523176A (ja) 2014-07-25 2017-08-17 シトムクス セラピューティクス，インコーポレイティド 抗−ｃｄ３抗体、活性化可能抗−ｃｄ３抗体、多重特異的抗−ｃｄ３抗体、多重特異的活性化可能抗−ｃｄ３抗体、及びそれらの使用方法
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016016114A2 (pt) * 2014-01-15 2018-05-22 Zymeworks Inc Construtos de ligação a antígeno cd19 e cd3 bi- específico.
DK3353212T3 (da) * 2015-09-23 2021-12-20 Regeneron Pharma Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
WO2019126576A1 (en) * 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
AU2020382621A1 (en) * 2019-11-13 2022-06-02 Amunix Pharmaceuticals, Inc. Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511521A (ja) 2005-10-11 2009-03-19 ミクロメット・アクチェンゲゼルシャフト 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
JP2014519322A (ja) 2011-05-16 2014-08-14 フェイビオン ファーマシューティカルズ， インコーポレイテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP2017523176A (ja) 2014-07-25 2017-08-17 シトムクス セラピューティクス，インコーポレイティド 抗−ｃｄ３抗体、活性化可能抗−ｃｄ３抗体、多重特異的抗−ｃｄ３抗体、多重特異的活性化可能抗−ｃｄ３抗体、及びそれらの使用方法
JP2018533909A (ja) 2015-08-28 2018-11-22 アムニクス オペレーティング インコーポレイテッド キメラポリペプチドアセンブリーならびにそれを作製および使用する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews，2013年，65，pp.1357-1369，<URL: http://tayatoru.blog62.fc2.com/blog-entry-1230.html>
薬剤学，2012年，72(5)，pp.276-282

Also Published As

Publication number Publication date
KR20220038068A (ko) 2022-03-25
JP2022537824A (ja) 2022-08-30
CO2022000406A2 (es) 2022-05-31
WO2020264200A1 (en) 2020-12-30
US20210054077A1 (en) 2021-02-25
AU2020308868A1 (en) 2022-01-20
CN115175933A (zh) 2022-10-11
JP2025106277A (ja) 2025-07-15
BR112021026089A2 (pt) 2022-03-22
PE20220600A1 (es) 2022-04-25
DOP2021000264A (es) 2022-05-15
IL289102A (en) 2022-02-01
PH12021500051A1 (en) 2023-01-23
CA3143519A1 (en) 2020-12-30
US20230121775A1 (en) 2023-04-20
CR20210628A (es) 2022-03-22
MX2021015880A (es) 2022-03-22
CL2021003448A1 (es) 2022-09-09
ECSP22005986A (es) 2022-04-29
EP3990497A4 (en) 2023-07-19
EP3990497A1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
JP7651481B2 (ja) Ｃｄ３抗原結合断片およびそれを含む組成物
US20250163153A1 (en) Release segments and binding compositions comprising same
TWI744247B (zh) 嵌合多肽組合體以及其製備及使用方法
JP2021176880A (ja) Ｉｌ−１５ベース分子及びその使用方法
US20230312729A1 (en) Egfr antigen binding fragments and compositions comprising same
AU2023201227B2 (en) Chimeric polypeptide assembly and methods of making and using the same
KR20250148642A (ko) 작용제, 방법 및 이의 용도
HK40081669A (en) Chimeric polypeptide assembly and methods of making and using the same
BR112018004045B1 (pt) Construto de conjunto de polipeptídeo quimérico e seu uso
BR122025010451A2 (pt) Conjunto de polipeptídeo quimérico, seu uso, composição farmacêutica e ácido nucleico isolado

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240904

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20241101

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250313

R150 Certificate of patent or registration of utility model

Ref document number: 7651481

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150